---
created: 2025-04-13
updated: 2025-04-13T10:53
id: p-m*qtwJUX
specialty: pharmaco
specialty_id: 361
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::01-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites::pyrimidine-synthesis-inhibitors::methotrexate
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::5-fu-methotrexate-leucovorin-hydroxyurea
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::01-antimetabolites::01-methotrexate,-leucovorin,-5-fluorouracil,-hydroxyurea::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
As an antineoplastic, Methotrexate is primarily indicated for cancers of lymphocytes, particularly **leukemias** and **lymphomas**

---

# Answer
